Peptides & the FDA review: your questions, answered

Not on the July 2026 agenda. A later review is anticipated (reported as early 2027); no official FDA date was confirmed as of July 2026.^{1 2}

MGF (mechano growth factor) is a natural splice variant of IGF-1 that muscle makes locally after loading or injury. PEG-MGF is a synthetic, pegylated version of the MGF E-domain peptide designed to last longer.^{3 4}

PEG-MGF is not an FDA-approved drug and has no cleared compounding pathway. It was removed from Category 2 in April 2026 but is not on the July 2026 agenda; a later review is expected.^{2 1}